1-20 of 104
Sort by
News

Phase II CAPTIVATE Study: The 5.5-Year Update

Lara C. Pullen, PhD
Published: 2024
Abstract
Mid-July 2024
View News titled, Phase II CAPTIVATE Study: The 5.5-Year Update
News

Fewer Patients With CLL/SLL Switch From Zanubrutinib to Another BTKi

Ruth Jessen Hickman, MD
Published: 2024
Abstract
Mid-July 2024
View News titled, Fewer Patients With CLL/SLL Switch From Zanubrutinib to Another BTKi
News

Asciminib More Effective, Safer Than Frontline Tyrosine Kinase Inhibitors for CML

Katie Robinson
Published: 2024
Abstract
Mid-July 2024
View News titled, Asciminib More Effective, Safer Than Frontline Tyrosine Kinase Inhibitors for CML
News

AI Electrocardiography Predicts Atrial Fibrillation Risk in Patients with CLL

Lara C. Pullen, PhD
Published: 2024
Abstract
July 2024
View News titled, AI Electrocardiography Predicts Atrial Fibrillation Risk in Patients with CLL
News

KIR3DL1-HLA-Bw Status in CML Is Associated With Achievement of Treatment-Free Remission

Lara C. Pullen, PhD
Published: 2024
Abstract
May 2024
View News titled, KIR3DL1-HLA-Bw Status in CML Is Associated With Achievement of Treatment-Free Remission
News

In the Long Run, Ibrutinib Brings Disease Control, but Cardiac Risks, in Older Patients with Untreated CLL

Thomas R. Collins
Published: 2024
Abstract
March 2024
View News titled, In the Long Run, Ibrutinib Brings Disease Control, but Cardiac Risks, in Older Patients with Untreated CLL
News

Researchers Identify Possible New Targets in CLL Subtypes

Thomas R. Collins
Published: 2023
Abstract
January Supplement 2024
View News titled, Researchers Identify Possible New Targets in CLL Subtypes
News

Prognostic Testing Underused for Patients with CLL/SLL

Lara C. Pullen, PhD
Published: 2023
Abstract
January Supplement 2024
View News titled, Prognostic Testing Underused for Patients with CLL/SLL
News

Flow Cytometry Identified as Less Expensive Method to Learn IGHV Status in CLL

Thomas R. Collins
Published: 2023
Abstract
January Supplement 2024
View News titled, Flow Cytometry Identified as Less Expensive Method to Learn IGHV Status in CLL
News

Global Real-World Patient Survey Identifies Need for Support, Patient Education in CLL

Anna Azvolinsky, PhD
Published: 2023
Abstract
January Supplement 2024
View News titled, Global Real-World Patient Survey Identifies Need for Support, Patient Education in CLL
News

Signs of Restored Immune System Seen After Ibrutinib, Venetoclax in Chronic Lymphocytic Leukemia

Thomas R. Collins
Published: 2023
Abstract
January Supplement 2024
View News titled, Signs of Restored Immune System Seen After Ibrutinib, Venetoclax in Chronic Lymphocytic Leukemia
News

Review Analyzes Cardiovascular Toxicities Associated With Bruton Tyrosine Kinase Inhibitors in CLL

Anna Azvolinsky, PhD
Published: 2023
Abstract
January Supplement 2024
View News titled, Review Analyzes Cardiovascular Toxicities Associated With Bruton Tyrosine Kinase Inhibitors in CLL
News

CD19 CAR T-Cell Therapy for CLL Shows Durable Response

Published: 2023
Abstract
January Supplement 2024
View News titled, CD19 CAR T-Cell Therapy for CLL Shows Durable Response
News

Sequencing of Patient Samples Shows Genetic Events Linked to Venetoclax-Resistant CLL

Katie Robinson
Published: 2023
Abstract
January Supplement 2024
View News titled, Sequencing of Patient Samples Shows Genetic Events Linked to Venetoclax-Resistant CLL
News

Nearly Two Decades of Data Show Long-Term Remissions From FCR for IGHV-Mutated Chronic Lymphocytic Leukemia

Leah Lawrence
Published: 2023
Abstract
January Supplement 2024
View News titled, Nearly Two Decades of Data Show Long-Term Remissions From FCR for IGHV-Mutated Chronic Lymphocytic Leukemia
News

High Karyotypic Complexity, Isolated Translocations Are Prognostic Factors in Venetoclax-Treated CLL

Katie Robinson
Published: 2023
Abstract
January Supplement 2024
View News titled, High Karyotypic Complexity, Isolated Translocations Are Prognostic Factors in Venetoclax-Treated CLL
News

Detailed Safety Analysis Underscores Superiority of Acalabrutinib vs. Ibrutinib

Lara C. Pullen, PhD
Published: 2023
Abstract
January Supplement 2024
View News titled, Detailed Safety Analysis Underscores Superiority of Acalabrutinib vs. Ibrutinib
News

Vibecotamab Shown to Be Effective Treatment for MDS, CMML

Lara C. Pullen, PhD
Published: 2023
Abstract
January 2024
View News titled, Vibecotamab Shown to Be Effective Treatment for MDS, CMML
News

Pirtobrutinib Effective in CLL/SLL After cBTKi, Analysis Shows

Thomas R. Collins
Published: 2023
Abstract
January 2024
View News titled, Pirtobrutinib Effective in CLL/SLL After cBTKi, Analysis Shows
News

MRD-Directed Combo of Ibrutinib Plus Venetoclax Improves PFS, OS Among Patients With Treatment-Naïve CLL

Anna Azvolinsky, PhD
Published: 2023
Abstract
January 2024
View News titled, MRD-Directed Combo of Ibrutinib Plus Venetoclax Improves PFS, OS Among Patients With Treatment-Naïve CLL